Restylane®Lidocain and Perlane®Lidocain approved in USA

Restylane®Lidocain and Perlane®Lidocain has been approved by FDA

(U.S. Food and Drug Administration). The products will now be available on the
US market by Q-Meds partner Medicis. Lidocain is a local anaesthetic.In clinical
studies supporting approval, the addition of lidocaine to Restylane and Perlane
substantially reduced pain experienced by patients.



Please read the full press release from Medicis:

http://www.irconnect.com/mrx/pages/news_releases.html?d=183418




Queries should be addressed to:

Alexander Kotsinas, Vice President and CFO

Tel: +46 (0)73-500 1111



Bengt Ågerup, President and CEO

Tel: +46 (0)70-974 9025





Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA(TM), for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR,

(a malformation of the urinary bladder) in children, andSolesta(TM) for the
treatment of fecal incontinence. Sales are made through the company's own
subsidiaries or distributors in over 70 countries. Q‑Med today has about 650
coworkers, with approximately 400 at the company's head office and production
facility in Uppsala, Sweden.

Q-Med AB is listed in the Mid Cap segment of theNASDAQ OMX Nordic.




Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden.Corporate identity
                              number 556258-6882.

      Tel: +46 18 474 90 00. Fax: +46 18 474 90 01.E-mail: info@q-med.com
      <mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.




[HUG#1380440]